Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection

被引：8
|
作者：
Nirei, Kazushige [1 ]
Nakamura, Hitomi [1 ]
Matsuoka, Shunichi [1 ]
Yamana, Yoichiro [1 ]
Yoda, Shunichi [2 ]
Hirayama, Atsushi [2 ]
Moriyama, Mitsuhiko [1 ]
机构：
[1] Nihon Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Tokyo, Japan
[2] Nihon Univ, Sch Med, Dept Med, Div Cardiol, Tokyo, Japan
来源：
INTERNAL MEDICINE | 2017年 / 56卷 / 07期
关键词：
chronic hepatitis C; ledipasvir and sofosbuvir; ventricular tachycardia; C VIRUS-INFECTION; AMIODARONE; MECHANISMS;
D O I：
10.2169/internalmedicine.56.7948
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We experienced two patients with serious arrhythmias associated with the administration of ledipasvir (LDV) and sofosbuvir (SOF). Neither patient took amiodarone, an agent for which concomitant use is prohibited. One patient was 82 years old and hypertensive; the other was 72 years old and had no cardiovascular risk factors such as hypertension or diabetes mellitus. The arrhythmias were both serious ventricular tachycardia (VT) that converted spontaneously to sinus rhythm, without treatment, and both patients had good outcomes. These cases suggest that LDV/SOF may be associated with an increased risk of heart-related events.
引用
收藏
页码：787 / 790
页数：4
相关论文
共 50 条
  • [41] Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir and HIV Antiviral Regimens in Subjects with HCV/HIV Co-infection
    German, Polina
    Ni, Liyun
    Stamm, Luisa M.
    Yang, Jenny C.
    Lenoci, Maryanne
    Ling, John
    Mathias, Anita
    HEPATOLOGY, 2015, 62 : 768A - 769A
  • [42] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection (vol 370, pg 1483, 2014)
    Afdhal, N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (06): : 584 - 584
  • [43] The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease
    Simon, Tracey G.
    Kim, Arthur Y.
    Stamm, Luisa M.
    Liu, Lin
    Mo, Hongmei
    Doehle, Brian
    Pang, Phillip S.
    Brainard, Diana M.
    McHutchison, John G.
    Gustafson, Jenna
    Lauer, Georg M.
    Chung, Raymond T.
    ANTIVIRAL THERAPY, 2016, 21 (03) : 185 - 194
  • [44] Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials
    Alqahtani, Saleh
    Afdhal, Nezam H.
    Zeuzem, Stefan
    Gordon, Stuart C.
    Mangia, Alessandra
    Kwo, Paul Y.
    Yang, Jenny C.
    Ding, Xiao
    Pang, Phillip S.
    McHutchison, John G.
    Marcellin, Patrick
    Kowdley, Kris V.
    Sulkowski, Mark S.
    HEPATOLOGY, 2014, 60 : 1140A - 1141A
  • [45] Efficacy of sofosbuvir and ledipasvir in an HCV plus gastro-resected patient
    Taibi, C.
    Tempestilli, M.
    D'Avolio, A.
    Garbuglia, A. R.
    De Nicolo, A.
    Montalbano, M.
    D'Offizi, G.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (05) : 621 - 623
  • [46] Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients
    Levitsky, Josh
    Verna, Elizabeth C.
    O'Leary, Jacqueline G.
    Bzowej, Natalie H.
    Moonka, Dilip K.
    Hyland, Robert H.
    Arterburn, Sarah
    Dvory-Sobol, Hadas
    Brainard, Diana M.
    McHutchison, John G.
    Terrault, Norah A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2106 - 2108
  • [47] The characteristics of patients in whom Sofosbuvir and Ledipasvir therapy failed to eradicate HCV
    Mawatari, Seiichi
    Moriuchi, Akihiro
    Kasai, Ai
    Ijuin, Sho
    Sakae, Haruka
    Tabu, Kazuaki
    Oda, Kohei
    Tamai, Tsutomu
    Ido, Akio
    HEPATOLOGY, 2017, 66 : 601A - 602A
  • [48] Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
    Kowdley, Kris V.
    Gordon, Stuart C.
    Reddy, K. Rajender
    Rossaro, Lorenzo
    Bernstein, David E.
    Lawitz, Eric
    Shiffman, Mitchell L.
    Schiff, Eugene
    Ghalib, Reem
    Ryan, Michael
    Rustgi, Vinod
    Chojkier, Mario
    Herring, Robert
    Di Bisceglie, Adrian M.
    Pockros, Paul J.
    Subramanian, G. Mani
    An, Di
    Svarovskaia, Evguenia
    Hyland, Robert H.
    Pang, Phillip S.
    Symonds, William T.
    McHutchison, John G.
    Muir, Andrew J.
    Pound, David
    Fried, Michael W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20): : 1879 - 1888
  • [49] Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
    Do, Albert
    Mittal, Yash
    Liapakis, AnnMarie
    Cohen, Elizabeth
    Chau, Hong
    Bertuccio, Claudia
    Sapir, Dana
    Wright, Jessica
    Eggers, Carol
    Drozd, Kristine
    Ciarleglio, Maria
    Deng, Yanhong
    Lim, Joseph K.
    PLOS ONE, 2015, 10 (08):
  • [50] Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
    Gary P. Wang
    Norah Terrault
    Jacqueline D. Reeves
    Lin Liu
    Eric Li
    Lisa Zhao
    Joseph K. Lim
    Giuseppe Morelli
    Alexander Kuo
    Josh Levitsky
    Kenneth E. Sherman
    Lynn M. Frazier
    Ananthakrishnan Ramani
    Joy Peter
    Lucy Akuskevich
    Michael W. Fried
    David R. Nelson
    Scientific Reports, 8
12345